a2m
  • a2m
  • Services
    • Strategy
    • Market Access and Reimbursement
    • Health Economic Modelling
    • Pricing and Valuation
    • Biotechnology
    • Nutrition
  • Capabilities
  • Latest News
  • About
  • Publications
  • Achievements
  • Contact
  • Home
  • Latest News

Latest News

Integrated Valuation Model - V4A2M Model

11 October 2022
Mark Nuijten

Lees meer

Mark Nuijten EPA 2021

13 April 2021
Mark Nuijten

An innovative pricing model to assess the price of expensive drugs with an orphan indication

Lees meer

Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases

3 December 2020
Mark Nuijten

Lees meer

Guest lecture for Colombian American Chamber of Commerce on Pricing Policy for Orphan Drugs

25 November 2020
Mark Nuijten

Lees meer

Milestone of more than 10’000 views on our policy paper challenging the ICER

12 September 2020
Mark Nuijten

Lees meer

International Market Access Update

1 January 2019
Mark Nuijten

Lees meer

Economic impact of macrosomia

10 August 2018
Mark Nuijten

Lees meer

Increasing interest in our Pricing Model and Algorithm for "expensive" drugs

1 April 2018
Mark Nuijten

Lees meer

The true prices of drugs

1 December 2016
Mark Nuijten

Lees meer

A2M - Minerva in Vienna at ISPOR

2 November 2016
Mark Nuijten

Lees meer

  • «
  • 1
  • 2
  • 3
  • »
Auteurs
  • Mark Nuijten
Latest News Blog
  • 11
    Oct
    Integrated Valuation Model - V4A2M Model
  • 13
    Apr
    Mark Nuijten EPA 2021
  • 3
    Dec
    Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases
Copyright by a2m, Mark Nuijten, 2018. All rights reserved.